Get in Touch
Execution Risk Consulting

Execution risk
is diagnosable
before it becomes
a crisis.

Inflection Strategy helps biotech companies approaching Phase 2 readouts, Phase 3 readouts, PDUFA dates, and commercial launches identify and resolve organizational gaps before they compound into failure.

Where execution fails, talent was load-bearing.

338 Diagnostic
Questions
A · Strategy B · Leadership C · Regulatory D · Clinical E · CMC / Mfg F · Finance G · Biostatistics H · IR / Comms K · Market Access L · Med Affairs M · Commercial N · Pharmacovigilance O · AI Governance P · Clinical Data
25+
Years in Life Sciences
22
Diagnostic Domains
338
Diagnostic Questions

They rarely fail
because of science.

Biotech organizations approaching their most critical inflection points — Phase 2 readouts, Phase 3 readouts, PDUFA dates, commercial launches — rarely fail because of the molecule. They fail because the organizational infrastructure wasn't ready. Execution risk accumulates silently across 16 organizational domains. Our proprietary Inflection Strategy Framework surfaces those vulnerabilities before they become public failures, giving leadership the runway to act.

The ISF is most valuable 6–18 months before an inflection event — when the findings can still drive remediation, not post-mortem. The same gap that looks manageable at 18 months becomes a crisis at 6. The window is real, and it closes.

The patterns that
repeat. Every time.

These are not hypothetical risks. They are the documented failure patterns of late-stage biotech companies that had the science — and lost the inflection. The ISF is calibrated to find them before they cost you the readout, the approval, or the launch.

Domain A · Leadership

The CEO, CMO, and CCO describe different priorities and decision criteria when interviewed separately. No one on the team knows this — until the moment of maximum external pressure.

Domain A · Scenario Readiness

The board has not reviewed or pre-authorized contingency plans for the most likely adverse outcome. When the readout comes, the organization spends the first 72 hours seeking alignment that should have been pre-built.

Domain I · Regulatory Affairs

No single executive owns the FDA response protocol. Accountability is shared across regulatory, legal, and medical — which means when an unexpected data query arrives, the response fragments along functional lines.

Cross-Domain · Seam Risk

Regulatory and commercial planning are running on separate timelines with separate assumptions. Neither team knows the other's critical path. The failure will happen at the interface, not inside either function.

Domain K · Market Access

Market access and HEOR were not involved in clinical data architecture decisions. Post-approval, the commercial analytics team inherits a dataset designed for endpoint validation — not payer segmentation or outcomes evidence.

Domain H · Investor Relations

The investor communication sequence for the PDUFA decision has not been rehearsed. IR, legal, and the CEO have not pre-aligned on disclosure triggers. Conflicting signals reach institutional holders within hours of the decision.

A 16-domain
diagnostic system.

The Inflection Strategy Framework is a 338-question, 80-sub-domain organizational diagnostic. It is not a consulting template. It is a structured methodology for seeing what is missing when the clock is running — and quantifying the risk before it surfaces publicly.

22
Domains (A–V)
338
Diagnostic Questions
80
Sub-Domains
A
Leadership & Executive Alignment
B
Commercial & Market Readiness
C
Regulatory Strategy & FDA Relationships
D
Medical Affairs & Scientific Communication
E
Biostatistics & Biometrics
F
Narrative & Assumption Governance
G
Organizational Structure & Human Capital
H
Investor Relations
I
Regulatory Affairs
J
CMC / Manufacturing
K
Market Access & HEOR
L
Medical Affairs Field Execution
M
Commercial Operations & Analytics
N
Pharmacovigilance
O
AI Governance & Digital Infrastructure Readiness
P
Clinical Data Infrastructure & Trial Operations Readiness

Three signal levels.
Each with a different action requirement.

Domain scoring is not a grade — it is an operational directive. Each signal level tells your leadership team what to do, not just what was found. The output is a written engagement report built for the CEO and board, not a consulting artifact.

Elevated Risk

Prioritize immediately

One or more red-flag thresholds crossed. Represents a material execution risk likely to manifest at the inflection event. Requires executive-level intervention and a named remediation owner within 30 days.

Watch

Assign and monitor

Conditions present that could escalate under pressure. No red flags crossed, but incomplete governance or cross-functional alignment creates latent risk. Requires named owners and 30-day checkpoint cadence.

Clear

Confirm and document

Domain governance is in place, documented, and stress-tested within the past quarter. Confirmation that this domain will not be a constraint at the inflection event. No further action required at this time.

A diagnostic instrument,
not a template.

Most consulting frameworks live in slide decks. The ISF operates through a purpose-built session instrument — capturing signals, scoring domains, assessing seam vulnerabilities, and generating a structured report in real time, during the executive interview itself.

V2.0  ·  22 Domains  ·  338 Questions  ·  Session Persistence  ·  PDF Export

')" title="Click to view full size">
Session setup — company, asset, inflection type, domain scoping
')" title="Click to view full size">
Sub-domain breakdown — observations, signal levels, red-flag thresholds
')" title="Click to view full size">
Generated signal report — domain map, seam risks, next steps
I
22 Domains · 338 Questions
Every diagnostic question built in — organized by domain and sub-domain, with red-flag thresholds visible during the session.
II
Real-Time Signal Capture
Domain and sub-domain signals scored live during executive interviews. Seam vulnerability assessment embedded alongside domain scoring.
III
Session Persistence
Multi-day, multi-tier engagements fully preserved across sessions. Load any prior session and resume exactly where you left off.
IV
PDF Signal Report
Generates a structured signal report — domain map, seam risk summary, prioritized next steps — exportable to PDF for board presentation.
For Advisory Firms & Investment Professionals

License the ISF Simulator for your practice.

Strategy consultants, M&A advisors, and investment firms conducting pre-deal or portfolio operational reviews can license the ISF Simulator as a standalone diagnostic instrument — deploying it across client engagements under a structured annual license. The Simulator provides the session capture, signal scoring, and report generation infrastructure. The ISF methodology provides the diagnostic architecture.

Licensing Inquiry
For Life Science Companies

Know where your execution risk lives — craft and execute a readiness plan before your board asks.

Late-stage biotechs and commercial-stage pharma companies can license the ISF Simulator enterprise-wide — giving CEOs, COOs, CCOs, and CFOs a shared diagnostic architecture for tracking readiness across all 22 domains. Run it as a pre-inflection operational audit, a quarterly cross-functional alignment tool, or standing board and investor prep. The Simulator captures the signal. Your leadership team acts on it.

Licensing Inquiry

How we work.

Engagements are structured around your inflection timeline. We identify the risk, quantify it, and when needed, help you act on it — through our integrated advisory and executive search capabilities.

01

Readiness Diagnostic

A structured ISF assessment across all 22 domains, delivered as a scored gap analysis with prioritized risk recommendations. The foundation of every engagement.

Step 0 Calibration
02

Strategic Advisory

Embedded advisory support as you navigate pre-launch execution. Scenario planning, cross-functional coordination, and executive counsel during the critical 12–24 month window.

Ongoing Engagement
03

Executive Search & Talent

When the diagnostic reveals human capital gaps, our executive search practice — operating as the talent arm of Inflection Strategy — helps source and place the senior commercial, medical, and market access leaders you need.

Recruit LS Division

Larry Chaityn
Principal

I have spent 25 years at the intersection of strategy, talent, and commercial execution in life sciences — as a business development advisor at Oracle Life Sciences and Cap Gemini, as a senior executive recruiter across pharma and biotech, and as an angel investor and CEO coach.

"The same gap that looked manageable at 18 months out becomes a crisis at 6 months. The window to act is real."

That vantage point — across dozens of organizations at their most pressured moments — is where the Inflection Strategy Framework was born. I have seen the same execution failures repeat across organizations of different sizes and therapeutic areas. They are not random. They are diagnosable.

My work is not turnaround consulting. It is pre-crisis diagnostic work — for organizations that are fundamentally sound but need a structured way to see their own blind spots before the clock runs out. The ISF is that structure.

When the diagnostic reveals a gap, I help think through how to close it — whether through advisory support, executive search, or, when the situation calls for it, working in an embedded capacity alongside the leadership team.

  • Business Development Advisory, Oracle Life Sciences & Cap Gemini
  • Executive Recruiting, The Steely Group & Recruit Life Sciences — placing senior leaders at critical inflection moments
  • Angel Investor & CEO Coach, New York Angel Investment Group
  • Architect of the Inflection Strategy Framework — 22 domains, 338 questions
  • Author, At the Inflection on Substack
  • 25+ years of life sciences proximity across BD, talent, and advisory
Thought Leadership

At the Inflection

Case studies of biotech organizational execution failures — and what they reveal about where late-stage companies are most vulnerable.

Read on Substack →

Built for organizations
approaching their moment.

I

Late-Stage Biotech & Specialty Pharma

Companies 12–24 months from a PDUFA date or commercial launch that need a structured view of organizational readiness before the pressure peaks.

II

CEOs, CCOs & CHROs

Senior executives who sense organizational gaps across functions but lack an independent diagnostic framework to surface, map, and prioritize them.

III

Investors & Boards

Investment partners and board members stress-testing pre-launch execution readiness — seeking an outside view before a critical binary event.

If you're approaching
a critical inflection,
let's talk.

Whether you're approaching a critical inflection, exploring the framework, or simply want to talk through an organizational challenge — reach out. Larry responds to every inquiry personally.

Location New York, NY
LinkedIn Larry Chaityn